- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
- Cancer1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
- Cancer1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- EGFR positive
- PD-L1 negative
- EGFR negative
- ER negative
- PR negative
- ALK negative
- KRAS positive
- BRAF positive
- CD20 positive
- BRCA1 positive
- ALK positive
- HLA positive
- BRCA2 positive
- HLA-A positive
- p16 positive
- BRAF negative
- MYC positive
- MET positive
- ROS1 negative
- CD19 positive
- HR positive
- TP53 positive
- IDH positive
- HLA negative
- PIK3CA positive
- RET positive
- p16 negative
- BCL2 positive
- ROS1 positive
- CD5 positive
- HLA-A negative
- IDH negative
- MET negative
- BCL6 positive
- ANA positive
- HPV positive
- NRAS positive
- PALB2 positive
- RB1 positive
- BCR-ABL1 positive
- FLT3 positive
- HPV negative
- KRAS negative
- MSS positive
- TP53 negative
- dMMR positive
- BRCA positive
- CCND1 positive
- CFTR positive
- Ex19del positive
- L858R positive
- NF1 positive
- NTRK positive
- RB1 negative
- RET negative
- BRCA1 negative
- CD4 positive
- FGFR2 positive
- HBsAg positive
- MMR negative
- MSI-H positive
- PTEN positive
- RAS positive
- SMN1 positive
- anti-dsDNA positive
- BRCA2 negative
- CLDN18.2 positive
- COL7A1 positive
- FLT3 negative
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- NF2 positive
- NRAS negative
- NTRK negative
- PMS2 positive
- TTR positive
- ctDNA positive
- ABCA4 positive
- ARID1A positive
- ATM positive
- CD19 negative
- CD20 negative
- CD30 positive
- FGFR3 positive
- GRN positive
- MDM2 positive
- MGMT negative
- Philadelphia chromosome negative
- RAS negative
- SMN2 positive
- T790M positive
- TROP2 negative
- TROP2 positive
- p53 positive
- pMMR positive
- t(11;14) positive
- 1p negative
- APOL1 positive
- APP positive
- BRCA negative
- C5 positive
- C9orf72 positive
- CD23 positive
- CD3 positive
- CDK12 positive
- DLL3 positive
- EBV positive
- EPCAM positive
- FMR1 positive
- FVIII positive
- GPC3 positive
- HR negative
- HRAS positive
- HTT positive
- JAK2 positive
- MGMT positive
- MSI negative
- MSI positive
- MSI-H negative
- NY-ESO-1 positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia chromosome positive
- PiZZ positive
- RAF positive
- RF positive
- RHO positive
- anti-Smith positive
- dMMR negative
- dsDNA positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- AGXT positive
- AKT negative
- ALPL positive
- ALT positive
- ASXL1 positive
- Aβ1-42 positive
- BAP1 positive
- BARD1 positive
- BRIP1 positive
- CD1a positive
- CD2 positive
- CD22 negative
- CD22 positive
- CD30 negative
- CD34 positive
- CD7 positive
- CD8 positive
- CD99 positive
- CDK4 positive
- CHEK1 positive
- CHEK2 positive
- COL1A1 positive
- COL1A2 positive
- DMD positive
- DNMT3A positive
- Del(17p) positive
- EBV DNA positive
- ER or PR positive
- ER/PR positive
- FANCA positive
- FANCL positive
- FGFR positive
- FOXO1 fusion negative
- G719X positive
- GBA positive
- GLA positive
- HBB positive
- HBV DNA negative
- HCG positive
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HbE positive
- HbSS positive
- IDS positive
- IGHV negative
- IL2RG positive
- IgHV positive
- KIT positive
- Ki-67 positive
- Ki67 positive
- L861Q positive
- MSS negative
- MTAP positive
- MYC negative
- NPM1 positive
- NRG1 positive
- NTRK1 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
7572 trials
1
2
3
…50